The review said a certain class of drugs had little clinical benefit, but many Alzheimer’s experts criticized the analysis, saying it unfairly lumped failed drugs with two recently approved treatments.
Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness
